<p>H.C. Wainwright 的分析师 Ram Selvaraju 对 Inhibikase Therapeutics (IKT) 发起了新的买入评级。</p>
<p>Ram Selvaraju 给予买入评级的原因是与 Inhibikase Therapeutics 的主打资产 IKT-001 及其在肺动脉高压 (PAH) 领域的后期开发路径相关的多种因素。他强调公司计划在 2026 年初直接将 IKT-001 推入全球关键的 3 期临床试验 (IMPROVE-PAH)，这反映了管理层和监管机构对该项目实力的信心。这种药物是一种新型的伊马替尼美克酸酯前药，旨在捕捉之前在 PAH 中观察到的伊马替尼的疗效信号，例如改善肺血管阻力和运动能力，同时解决之前导致高停药率的耐受性问题。Selvaraju 预计，重新配方的药物应显著减少胃肠道副作用，从而改善整体安全性和依从性。</p>
<p>Ram Selvaraju 还强调，FDA 已经提供了支持两部分自适应 3 期设计的指导，他认为这在战略上是有利的。该设计允许剂量优化、从 A 部分到 B 部分的无缝过渡，以及根据中期结果调整样本量的选项，这些都可以增强统计效能和开发效率。此外，公司在差异化剂型、优化制造和追求 505(b)(2) 监管路径方面的工作，使 IKT-001 有望成为一种具有加速和降低风险的市场准入新分子实体。综合来看，这些临床、监管和制造优势支撑了他对 Inhibikase 股票具有吸引力的上涨潜力的信念，支持了他的买入评级和 8 美元的目标价。</p>
<p>在 12 月 11 日发布的另一份报告中，Cantor Fitzgerald 也对该股票发起了覆盖，给予买入评级，目标价为 4.00 美元。</p>

<p>H.C. Wainwright 的 Ram Selvaraju 对 Inhibikase Therapeutics (IKT) 启动了买入评级，目标价为 8 美元，理由是 IKT-001 在肺动脉高压（PAH）方面的后期开发以及降低风险的 505(b)(2) 路径。该药物的三期临床试验计划于 2026 年初进行，FDA 支持采用两部分自适应设计。Cantor Fitzgerald 也给予了买入评级，目标价为 4 美元</p>

<p>Ram Selvaraju, an analyst from H.C. Wainwright, has initiated a new Buy rating on Inhibikase Therapeutics (IKT).</p>
<div class="lb-trans"><p>H.C. Wainwright 的分析师 Ram Selvaraju 对 Inhibikase Therapeutics (IKT) 发起了新的买入评级。</p>
</div><p>Ram Selvaraju has given his Buy rating due to a combination of factors related to Inhibikase Therapeutics’ lead asset, IKT-001, and its late-stage development pathway in pulmonary arterial hypertension (PAH). He highlights the company’s plan to move IKT-001 directly into a global, pivotal Phase 3 trial (IMPROVE-PAH) starting in early 2026, reflecting confidence from both management and regulators in the strength of the program. The drug is a novel prodrug form of imatinib mesylate, designed to capture the prior efficacy signals seen with imatinib in PAH—such as improvements in pulmonary vascular resistance and exercise capacity—while addressing tolerability issues that previously led to high discontinuation rates. Selvaraju expects that the reformulated agent should significantly reduce gastrointestinal side effects and thereby improve overall safety and adherence.</p>
<div class="lb-trans"><p>Ram Selvaraju 给予买入评级的原因是与 Inhibikase Therapeutics 的主打资产 IKT-001 及其在肺动脉高压 (PAH) 领域的后期开发路径相关的多种因素。他强调公司计划在 2026 年初直接将 IKT-001 推入全球关键的 3 期临床试验 (IMPROVE-PAH)，这反映了管理层和监管机构对该项目实力的信心。这种药物是一种新型的伊马替尼美克酸酯前药，旨在捕捉之前在 PAH 中观察到的伊马替尼的疗效信号，例如改善肺血管阻力和运动能力，同时解决之前导致高停药率的耐受性问题。Selvaraju 预计，重新配方的药物应显著减少胃肠道副作用，从而改善整体安全性和依从性。</p>
</div><p>Ram Selvaraju also emphasizes that the FDA has already provided guidance supporting a two-part adaptive Phase 3 design, which he views as strategically favorable. The design allows for dose optimization, seamless transition from Part A to Part B, and the option to refine sample size based on interim findings, all of which can enhance statistical power and development efficiency. Additionally, the company’s work on differentiated dosage forms, optimized manufacturing, and pursuit of a 505(b)(2) regulatory pathway positions IKT-001 as a potentially new molecular entity with an accelerated and de-risked route to market. Taken together, these clinical, regulatory, and manufacturing advantages underpin his conviction that Inhibikase shares offer attractive upside, supporting his Buy rating and $8 price target.</p>
<div class="lb-trans"><p>Ram Selvaraju 还强调，FDA 已经提供了支持两部分自适应 3 期设计的指导，他认为这在战略上是有利的。该设计允许剂量优化、从 A 部分到 B 部分的无缝过渡，以及根据中期结果调整样本量的选项，这些都可以增强统计效能和开发效率。此外，公司在差异化剂型、优化制造和追求 505(b)(2) 监管路径方面的工作，使 IKT-001 有望成为一种具有加速和降低风险的市场准入新分子实体。综合来看，这些临床、监管和制造优势支撑了他对 Inhibikase 股票具有吸引力的上涨潜力的信念，支持了他的买入评级和 8 美元的目标价。</p>
</div><p>In another report released on December 11, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $4.00 price target.</p>
<div class="lb-trans"><p>在 12 月 11 日发布的另一份报告中，Cantor Fitzgerald 也对该股票发起了覆盖，给予买入评级，目标价为 4.00 美元。</p>
</div>

Inhibikase Therapeutics: Late-Stage IKT-001 PAH Program and De-Risked 505(b)(2) Pathway Support Buy Rating and $8 Target

- H.C. Wainwright 的分析师 Ram Selvaraju 对 Inhibikase Therapeutics (IKT) 给出 Buy 评级。  
- 评级基于 IKT-001 在肺动脉高压的晚期开发计划与新设计的 3 期试验。  
- Cantor Fitzgerald 也在 12 月 11 日给予该股票 Buy 评级，目标价 $4.00。

Inhibikase Therapeutics：晚期 IKT-001 PAH 项目以及降低风险的 505(b)(2) 途径支持买入评级，目标价为 8 美元